Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis
Bin Tang,1 Jun Wang,1 Lin-lin Luo,1 Qiu-gen Li,1,* Dan Huang2,* 1Department of Respiratory Medicine, Jiangxi Provincial People’s Hospital Affiliated to Nanchang University, No. 92 Aiguo Road, Nanchang, 330006, Jiangxi, China; 2Department of Anesthesiology, The Second Affiliated Hospital o...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-04-01
|
| Series: | International Journal of COPD |
| Subjects: | |
| Online Access: | https://www.dovepress.com/risks-of-budesonideformoterol-for-the-treatment-of-stable-copd-a-meta--peer-reviewed-article-COPD |
| _version_ | 1818944794270892032 |
|---|---|
| author | Tang B Wang J Luo LL Li QG Huang D |
| author_facet | Tang B Wang J Luo LL Li QG Huang D |
| author_sort | Tang B |
| collection | DOAJ |
| description | Bin Tang,1 Jun Wang,1 Lin-lin Luo,1 Qiu-gen Li,1,* Dan Huang2,* 1Department of Respiratory Medicine, Jiangxi Provincial People’s Hospital Affiliated to Nanchang University, No. 92 Aiguo Road, Nanchang, 330006, Jiangxi, China; 2Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang, 330006, Jiangxi, China *These authors contributed equally to this work Purpose: The aim of this study was to investigate the comparative risks of budesonide/formoterol, versus placebo or monotherapies, for the treatment of patients with stable COPD.Materials and methods: We undertook a systematic search of the literature in PubMed, Embase, and the Cochrane Central Register of Controlled Trials, for randomized controlled trials (RCTs) comparing budesonide/formoterol with control regimens for the treatment of patients with stable COPD and at least 12 weeks of follow-up, meeting the inclusion criteria. Studies were reviewed, and OR with corresponding 95% CI was used to pool the results.Results: A total of eight studies involving 9,254 patients met the inclusion criteria of this meta-analysis. Compared with placebo, combination therapy with budesonide/formoterol was associated with a significantly higher risk of adverse effects including oral candidiasis (OR: 3.09, 95% CI: 1.95–4.91) and dysphonia (OR: 2.76, 95% CI: 1.40–5.44), but not pneumonia (OR: 0.94, 95% CI: 0.64–1.37) or bronchitis (OR: 1.36, 95% CI: 0.95–1.95). A similar pattern was also evident for the comparison of formoterol with budesonide/formoterol, with increased occurrence of oral candidiasis (OR: 2.72, 95% CI: 1.33–5.58) and dysphonia (OR: 4.13, 95% CI: 1.95–8.76); however, there were no significant differences in pneumonia (OR: 1.31, 95% CI: 0.98–1.74) or bronchitis (OR: 1.05, 95% CI: 0.83–1.31). In contrast, compared with budesonide, combined budesonide/formoterol was associated with similar risks of adverse effects, including pneumonia (OR: 1.20, 95% CI: 0.60–2.39), bronchitis (OR: 0.95, 95% CI: 0.41–2.20), oral candidiasis (OR: 0.79, 95% CI: 0.41–1.53), and dysphonia (OR: 1.00, 95% CI: 0.40–2.47).Conclusion: Combination therapy does not cause more adverse events, including pneumonia and bronchitis, than control (placebo, formoterol, or budesonide) treatment in patients with stable COPD, while there were higher risks of oral candidiasis and dysphonia compared with the non-inhaled corticosteroid group (placebo, formoterol). Keywords: budesonide/formoterol, risk, COPD, meta-analysis, randomized controlled trial |
| first_indexed | 2024-12-20T07:48:53Z |
| format | Article |
| id | doaj.art-b95295fd812542e683f6ba783a6e1e77 |
| institution | Directory Open Access Journal |
| issn | 1178-2005 |
| language | English |
| last_indexed | 2024-12-20T07:48:53Z |
| publishDate | 2019-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-b95295fd812542e683f6ba783a6e1e772022-12-21T19:47:54ZengDove Medical PressInternational Journal of COPD1178-20052019-04-01Volume 1475776644848Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysisTang BWang JLuo LLLi QGHuang DBin Tang,1 Jun Wang,1 Lin-lin Luo,1 Qiu-gen Li,1,* Dan Huang2,* 1Department of Respiratory Medicine, Jiangxi Provincial People’s Hospital Affiliated to Nanchang University, No. 92 Aiguo Road, Nanchang, 330006, Jiangxi, China; 2Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang, 330006, Jiangxi, China *These authors contributed equally to this work Purpose: The aim of this study was to investigate the comparative risks of budesonide/formoterol, versus placebo or monotherapies, for the treatment of patients with stable COPD.Materials and methods: We undertook a systematic search of the literature in PubMed, Embase, and the Cochrane Central Register of Controlled Trials, for randomized controlled trials (RCTs) comparing budesonide/formoterol with control regimens for the treatment of patients with stable COPD and at least 12 weeks of follow-up, meeting the inclusion criteria. Studies were reviewed, and OR with corresponding 95% CI was used to pool the results.Results: A total of eight studies involving 9,254 patients met the inclusion criteria of this meta-analysis. Compared with placebo, combination therapy with budesonide/formoterol was associated with a significantly higher risk of adverse effects including oral candidiasis (OR: 3.09, 95% CI: 1.95–4.91) and dysphonia (OR: 2.76, 95% CI: 1.40–5.44), but not pneumonia (OR: 0.94, 95% CI: 0.64–1.37) or bronchitis (OR: 1.36, 95% CI: 0.95–1.95). A similar pattern was also evident for the comparison of formoterol with budesonide/formoterol, with increased occurrence of oral candidiasis (OR: 2.72, 95% CI: 1.33–5.58) and dysphonia (OR: 4.13, 95% CI: 1.95–8.76); however, there were no significant differences in pneumonia (OR: 1.31, 95% CI: 0.98–1.74) or bronchitis (OR: 1.05, 95% CI: 0.83–1.31). In contrast, compared with budesonide, combined budesonide/formoterol was associated with similar risks of adverse effects, including pneumonia (OR: 1.20, 95% CI: 0.60–2.39), bronchitis (OR: 0.95, 95% CI: 0.41–2.20), oral candidiasis (OR: 0.79, 95% CI: 0.41–1.53), and dysphonia (OR: 1.00, 95% CI: 0.40–2.47).Conclusion: Combination therapy does not cause more adverse events, including pneumonia and bronchitis, than control (placebo, formoterol, or budesonide) treatment in patients with stable COPD, while there were higher risks of oral candidiasis and dysphonia compared with the non-inhaled corticosteroid group (placebo, formoterol). Keywords: budesonide/formoterol, risk, COPD, meta-analysis, randomized controlled trial https://www.dovepress.com/risks-of-budesonideformoterol-for-the-treatment-of-stable-copd-a-meta--peer-reviewed-article-COPDbudesonide/formoterolriskchronic obstructive pulmonary diseasemeta-analysisrandomized controlled trial |
| spellingShingle | Tang B Wang J Luo LL Li QG Huang D Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis International Journal of COPD budesonide/formoterol risk chronic obstructive pulmonary disease meta-analysis randomized controlled trial |
| title | Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis |
| title_full | Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis |
| title_fullStr | Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis |
| title_full_unstemmed | Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis |
| title_short | Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis |
| title_sort | risks of budesonide formoterol for the treatment of stable copd a meta analysis |
| topic | budesonide/formoterol risk chronic obstructive pulmonary disease meta-analysis randomized controlled trial |
| url | https://www.dovepress.com/risks-of-budesonideformoterol-for-the-treatment-of-stable-copd-a-meta--peer-reviewed-article-COPD |
| work_keys_str_mv | AT tangb risksofbudesonideformoterolforthetreatmentofstablecopdametaanalysis AT wangj risksofbudesonideformoterolforthetreatmentofstablecopdametaanalysis AT luoll risksofbudesonideformoterolforthetreatmentofstablecopdametaanalysis AT liqg risksofbudesonideformoterolforthetreatmentofstablecopdametaanalysis AT huangd risksofbudesonideformoterolforthetreatmentofstablecopdametaanalysis |